Vivani Medical (VANI) Maxim Group’s 2024 Healthcare Virtual Summit summary

Drug delivery technology and clinical rationale

• NanoPortal technology enables precise, consistent drug delivery with minimal fluctuation, supporting FDA IND clearance.

• Delivery rate and profile are controlled by nanotube parameters and formulation, allowing tailored dosing.

• Exenatide was chosen for its potency and expired patents, enabling access and smaller implant size for a given duration.

• Preclinical data show exenatide implant achieves weight loss and liver fat reduction comparable to semaglutide injections.

• A semaglutide implant (NPM-139) is also in development, potentially enabling once-yearly administration.

Market opportunity and treatment paradigm

• The technology targets the large GLP-1 market, aiming to address adherence challenges faced by previous approaches.

• Non-adherence affects about 50% of patients, reducing real-world efficacy compared to clinical trials.

• A six-month implant could improve compliance and outcomes, especially for patients struggling with regular dosing.

• Physician-administered implants offer assurance of adherence for patients and caregivers.

• The product is positioned as an additional option for patients needing long-term, reliable therapy.

Administration and training

• Implant procedure is similar to existing contraceptive implants, requiring about three hours of training.

• Nurse practitioners, PAs, and physicians can perform the procedure in minutes, with minimal patient time required.